Comparative Pharmacology
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus BKEMV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADEFOVIR DIPIVOXIL versus BKEMV.
ADEFOVIR DIPIVOXIL vs BKEMV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
BKEMV is a monoclonal antibody that binds to the extracellular domain of the HER2/neu receptor, inhibiting downstream signaling pathways including PI3K/Akt and MAPK, thereby reducing cell proliferation and promoting antibody-dependent cell-mediated cytotoxicity (ADCC).
10 mg orally once daily on an empty stomach.
Intravenous: 100 mg every 12 hours; oral: 50 mg twice daily.
None Documented
None Documented
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Terminal elimination half-life: 12-18 hours in healthy adults; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Renal excretion: 40-50% unchanged; biliary/fecal: 20-30% as metabolites; total clearance approximates renal clearance.
Category C
Category C
Antiviral
Antiviral, HIV